Skip to main content
. Author manuscript; available in PMC: 2014 Aug 6.
Published in final edited form as: Urology. 2013 Oct 19;83(2):312–319. doi: 10.1016/j.urology.2013.08.047

Table 3.

Lower urinary tract symptoms outcomes among 519,189 Iraq and Afghanistan male veterans in veterans affairs health care from 2001 to 2010, stratified by mental health status

No MH Diagnosis
(ref) (n = 299,459)
MH Diagnosis w/o PTSD
(n = 82,976)
PTSD (Including Other MH Diagnoses)
(n = 136,754)
Total
(n = 519,189)
Variables No. (%) No. (%) No. (%) No. (%)
LUTS diagnoses, related procedure, or prescription 3812 (1.3) 2580 (3.1)*** 4845 (3.5)*** 11,237 (2.2)
LUTS diagnosis 1941 (0.6) 1414 (1.7)*** 2397 (1.8)*** 5752 (1.1)
Urinary agents 1836 (0.6) 1266 (1.5)*** 2497 (1.8)*** 5599 (1.1)
5-Alpha reductase inhibitor 243 (0.1) 141 (0.2)*** 210 (0.2)*** 594 (0.1)
Alpha-1 adrenergic inhibitor 1,301 (0.5) 764 (1.1)*** 1,647 (1.3)*** 3712 (0.7)
Anticholinergics 427 (0.1) 466 (0.6)*** 775 (0.6)*** 1668 (0.3)
One or more LUTS-related procedures 1092 (0.4) 847 (1.0)*** 1533 (1.1)*** 3472 (0.7)

MH, mental health; other abbreviations as in Table 1.

***

P <.001 with “No MH Diagnosis” as the referent group.

Patients may have multiple diagnoses, medications prescribed, or procedures; accordingly, the number of unique patients reported for the category totals will be lower than the sum of the individual items in that category. The same holds true for the overall total.

Denominator for male-specific drugs and procedures is 263,676 men without any mental health diagnosis, 69,062 men with mental health diagnoses not including PTSD, and 123,602 men with mental health diagnoses including PTSD.